PFEPfizer Inc.

Asset classequitySectorhealthcareExchangeNYSECurrencyUSD

Pfizer Inc. (PFE) is a NYSE-listed equity covered by Valdrans. Last close $28.280, +1.65% on the day; +1.73% over 1 week, +2.02% over 4 weeks, +5.05% over 6 months (prices as of 9 Oct 2026). Valdrans Insider Activity Signal: Positive — 3 buys vs 1 sell disclosed in the last 90 days.

Last close (9 Oct 2026)
$28.280
Today
+1.65%
1 week
+1.73%
4 weeks
+2.02%
6 months
+5.05%
Latest coverage
PFE Q3 2026 update — filings and holdings
$28.280USD
+1.65% today
1 week+1.73%
4 weeks+2.02%
6 months+5.05%
2026-01-23 to 2026-10-09Range: $23.670 – $29.020Closing prices. Not real-time. Data via Yahoo Finance.

Coverage of PFE(16)

PFE Q3 2026 update — filings and holdings

PFE Q3 2026 update — filings and holdings

PFE Q3 2026 update — filings and holdings

PFE Q2 2026: filings, holdings, and macro context

PFE Q2 2026: filings, holdings, and macro context

PFE Q2 2026 update — filings and holdings

PFE Q2 2026 update — filings and holdings

PFE Q2 2026 update — filings and holdings

PFE Q2 2026 update — filings and holdings

PFE Q2 2026 update — filings and holdings

PFE Q2 2026 update — filings and holdings

PFE Q2 2026 update — filings and holdings

GSK's Bexsero chosen for UK MenB rollout to 1 million students

The NHS will offer GSK's two-dose Bexsero vaccine to around one million Year 13 pupils and under-25s starting university this autumn, following a meningitis B outbreak in Kent.

3 sources

PFE Q1 2026 update — filings and holdings

PFE Q1 2026: filings, holdings, and macro context

PFE Q1 2026 update — filings and holdings